Achillion to Report Second Quarter 2012 Financial Results and Host Conference Call on August 8, 2012

Conference Call and Live Webcast Will Begin at 10:00 a.m. EDT on August 8, 2012

        Print
| Source: Achillion Pharmaceuticals, Inc.

NEW HAVEN, Conn., July 31, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that it plans to release second quarter and six-month 2012 financial results on Wednesday, August 8, 2012, before the market opens.

Achillion will also host a conference call and live webcast to discuss these financial results and to provide an update on the Company's hepatitis C (HCV) development programs that morning at 10:00 a.m. EDT.

To participate in the conference call, please dial (877) 266-0482 in the U.S. or (631) 291-4567 for international callers. A live audio webcast of the call will be accessible at www.achillion.com, under the News Center section of the website. Please connect to Achillion's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

A replay of the webcast will be available on www.achillion.com. Alternatively, a replay of the conference call can be accessed beginning at 1:00 p.m. EDT on August 8, 2012, through 11:59 p.m. ET on August 15, 2012 by dialing (800) 585-8367 or (404) 537-3406 for international callers. The replay passcode is 13643523.

About Achillion Pharmaceuticals

Achillion is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. Achillion's proven discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused on solutions for the most challenging problems in infectious disease including hepatitis C and resistant bacterial infections. For more information on Achillion Pharmaceuticals, please visit www.achillion.com or call 1-203-624-7000.

Company Contact:
Glenn Schulman
Achillion Pharmaceuticals, Inc.
Tel. (203) 624-7000


Investors:
Mary Kay Fenton
Achillion Pharmaceuticals, Inc.
Tel. (203) 624-7000